Artificial intelligence platform developer Viz.ai announced that it raised $71 million in a Series C financing round.
San Francisco-based Viz.ai develops AI software for treating acute ischemic stroke. The software uses a computer-aided triage system to identify a suspected large-vessel occlusion via CT scan and alerts a stroke team specialist to reduce the time to treatment, according to the company.
With the funding raised in the series, Viz.ai is looking to accelerate the expansion of its Intelligent Care Coordination AI platform to other areas of acute care, including cardiology, pulmonary and trauma, according to a news release.
Scale Venture Partners and Insight Partners led the round, while Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures all participated. The round brings Viz.ai’s total funding to over $150 million, as the company raised a $50 million Series B in October 2019 and it reeled in $21 million in a Series A in July 2018.
In July 2019, Medtronic inked a deal to distribute Viz.ai’s stroke-detection software, saying it aimed to place the platform in every U.S. stroke center.
“This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination,” Viz.ai co-founder & CEO Chris Mansi said in the release. “The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe.”
The company also presented new data at the International Stroke Conference 2021 that highlighted positive patient outcomes.
Use of the Viz.ai technology to coordinate care for acute ischemic stroke, hemorrhagic stroke and clinical trial recruitment reduced door-in, door-out times, improved door-in-to-puncture times and resulted in higher rates of good reperfusion, the company said.
According to a news release, Dr. Brian Jankowitz of Cooper University Health Care in New Jersey highlighted that Viz.ai’s clinical trial enrollment software, Viz Recruit, led to faster patient detection and increased enrollment velocity, too.